

# David R Corey

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1903710/david-r-corey-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

133  
papers

9,563  
citations

50  
h-index

96  
g-index

139  
ext. papers

10,702  
ext. citations

10.7  
avg, IF

6.74  
L-index

#	Paper	IF	Citations
133	Non-coding RNAs as drug targets. <i>Nature Reviews Drug Discovery</i> , <b>2017</b> , 16, 167-179	64.1	492
132	RNA interference in mammalian cells by chemically-modified RNA. <i>Biochemistry</i> , <b>2003</b> , 42, 7967-75	3.2	466
131	Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. <i>Chemistry and Biology</i> , <b>2001</b> , 8, 1-7		461
130	Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. <i>Nature Chemical Biology</i> , <b>2007</b> , 3, 166-73	11.7	402
129	Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. <i>Nucleic Acids Research</i> , <b>2018</b> , 46, 1584-1600	20.1	345
128	Inhibition of human telomerase activity by peptide nucleic acids. <i>Nature Biotechnology</i> , <b>1996</b> , 14, 615-9	44.5	314
127	Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. <i>Nature Structural and Molecular Biology</i> , <b>2006</b> , 13, 787-92	17.6	270
126	Silencing disease genes in the laboratory and the clinic. <i>Journal of Pathology</i> , <b>2012</b> , 226, 365-79	9.4	267
125	RNAi factors are present and active in human cell nuclei. <i>Cell Reports</i> , <b>2014</b> , 6, 211-21	10.6	253
124	Antisense transcripts are targets for activating small RNAs. <i>Nature Structural and Molecular Biology</i> , <b>2008</b> , 15, 842-8	17.6	239
123	Novel antisense and peptide nucleic acid strategies for controlling gene expression. <i>Biochemistry</i> , <b>2002</b> , 41, 4503-10	3.2	230
122	Biodistribution of phosphodiester and phosphorothioate siRNA. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2004</b> , 14, 1139-43	2.9	222
121	Chemical modification: the key to clinical application of RNA interference?. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 3615-22	15.9	219
120	Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. <i>Cell</i> , <b>2012</b> , 150, 895-908	56.2	215
119	Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear factor-kappaB activation of cyclooxygenase 2 expression. <i>Molecular Endocrinology</i> , <b>2006</b> , 20, 2724-33		213
118	Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. <i>Nature Biotechnology</i> , <b>2009</b> , 27, 478-84	44.5	193
117	Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters. <i>Nucleic Acids Research</i> , <b>2011</b> , 39, 5682-91	20.1	150

116	Promoter RNA links transcriptional regulation of inflammatory pathway genes. <i>Nucleic Acids Research</i> , <b>2013</b> , 41, 10086-109	20.1	144
115	Inhibiting transcription of chromosomal DNA with antigene peptide nucleic acids. <i>Nature Chemical Biology</i> , <b>2005</b> , 1, 210-5	11.7	143
114	Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs. <i>Nature Chemical Biology</i> , <b>2005</b> , 1, 216-22	11.7	142
113	Cellular delivery of peptide nucleic acids and inhibition of human telomerase. <i>Chemistry and Biology</i> , <b>1999</b> , 6, 343-51		142
112	Inhibition of gene expression inside cells by peptide nucleic acids: effect of mRNA target sequence, mismatched bases, and PNA length. <i>Biochemistry</i> , <b>2001</b> , 40, 53-64	3.2	139
111	Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. <i>Nature Neuroscience</i> , <b>2017</b> , 20, 497-499	25.5	136
110	Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. <i>Nucleic Acids Research</i> , <b>2010</b> , 38, 7736-48	20.1	136
109	Telomerase inhibition by peptide nucleic acids reverses immortality of transformed human cells. <i>Oncogene</i> , <b>1999</b> , 18, 6191-200	9.2	130
108	The structure of a Michaelis serpin-protease complex. <i>Nature Structural Biology</i> , <b>2001</b> , 8, 979-83		125
107	Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. <i>Biochemistry</i> , <b>2010</b> , 49, 10166-78	3.2	116
106	Analysis of nuclear RNA interference in human cells by subcellular fractionation and Argonaute loading. <i>Nature Protocols</i> , <b>2014</b> , 9, 2045-60	18.8	111
105	Morpholino antisense oligonucleotides: tools for investigating vertebrate development. <i>Genome Biology</i> , <b>2001</b> , 2, REVIEWS1015	18.3	110
104	Synthesis and membrane permeability of PNA-peptide conjugates. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>1997</b> , 7, 3001-3006	2.9	94
103	Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning. <i>Biochemistry</i> , <b>1997</b> , 36, 11873-80	3.2	92
102	Transcriptional regulation by small RNAs at sequences downstream from 3' gene termini. <i>Nature Chemical Biology</i> , <b>2010</b> , 6, 621-9	11.7	89
101	Challenges for RNAi in vivo. <i>Trends in Biotechnology</i> , <b>2004</b> , 22, 390-4	15.1	88
100	Telomerase inhibition, oligonucleotides, and clinical trials. <i>Oncogene</i> , <b>2002</b> , 21, 631-7	9.2	86
99	Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. <i>Nucleic Acids Research</i> , <b>2002</b> , 30, 5160-7	20.1	86

98	Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. <i>Biochemistry</i> , <b>2002</b> , 41, 9973-81	3.2	84
97	Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. <i>Chemistry and Biology</i> , <b>2010</b> , 17, 1183-8		79
96	Inhibiting gene expression with peptide nucleic acid (PNA)--peptide conjugates that target chromosomal DNA. <i>Biochemistry</i> , <b>2007</b> , 46, 7581-9	3.2	78
95	RNA learns from antisense <b>2007</b> , 3, 8-11		77
94	Enhancement of strand invasion by oligonucleotides through manipulation of backbone charge. <i>Nature Biotechnology</i> , <b>1996</b> , 14, 1700-4	44.5	74
93	Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter. <i>Chemistry and Biology</i> , <b>2010</b> , 17, 1344-55		71
92	Regulation of mammalian transcription and splicing by Nuclear RNAi. <i>Nucleic Acids Research</i> , <b>2016</b> , 44, 524-37	20.1	67
91	Intracellular uptake and inhibition of gene expression by PNAs and PNA-peptide conjugates. <i>Biochemistry</i> , <b>2004</b> , 43, 14340-7	3.2	67
90	Expanding the action of duplex RNAs into the nucleus: redirecting alternative splicing. <i>Nucleic Acids Research</i> , <b>2012</b> , 40, 1240-50	20.1	58
89	Design and bioinformatics analysis of genome-wide CLIP experiments. <i>Nucleic Acids Research</i> , <b>2015</b> , 43, 5263-74	20.1	57
88	Predicting potential miRNA target sites within gene promoters. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2009</b> , 19, 3791-4	2.9	56
87	Activating frataxin expression by repeat-targeted nucleic acids. <i>Nature Communications</i> , <b>2016</b> , 7, 10606	17.4	55
86	Strand invasion by mixed base PNAs and a PNA-peptide chimera. <i>Nucleic Acids Research</i> , <b>2000</b> , 28, 3332-8	20.1	55
85	Clinical status of duplex RNA. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2010</b> , 20, 3203-7	2.9	53
84	Synthesis, analysis, purification, and intracellular delivery of peptide nucleic acids. <i>Methods</i> , <b>2001</b> , 23, 97-107	4.6	52
83	The 10th Oligonucleotide Therapy Approved: Golodirsén for Duchenne Muscular Dystrophy. <i>Nucleic Acid Therapeutics</i> , <b>2020</b> , 30, 67-70	4.8	50
82	Argonaute and the nuclear RNAs: new pathways for RNA-mediated control of gene expression. <i>Nucleic Acid Therapeutics</i> , <b>2012</b> , 22, 3-16	4.8	49
81	Digital quantitation of potential therapeutic target RNAs. <i>Nucleic Acid Therapeutics</i> , <b>2013</b> , 23, 188-94	4.8	47

80	Liver cell specific targeting of peptide nucleic acid oligomers. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2001</b> , 11, 1269-72	2.9	46
79	Automated synthesis of peptide nucleic acids and peptide nucleic acid-peptide conjugates. <i>Analytical Biochemistry</i> , <b>1999</b> , 268, 401-4	3.1	45
78	Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs. <i>Biological Chemistry</i> , <b>2011</b> , 392, 315-25	4.5	43
77	Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology. <i>Journal of Nuclear Medicine</i> , <b>2002</b> , 43, 948-56	8.9	43
76	Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. <i>Cancer Research</i> , <b>2003</b> , 63, 5917-25	10.1	42
75	Telomeres and telomerase: from discovery to clinical trials. <i>Chemistry and Biology</i> , <b>2009</b> , 16, 1219-23		40
74	Specific and nonspecific inhibition of transcription by DNA, PNA, and phosphorothioate promoter analog duplexes. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>1996</b> , 6, 2897-2900	2.9	39
73	Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. <i>Annals of the New York Academy of Sciences</i> , <b>2009</b> , 1175, 24-31	6.5	38
72	Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters. <i>Nucleic Acids Research</i> , <b>2010</b> , 38, 5242-59	20.1	37
71	Silencing gene expression by targeting chromosomal DNA with antigene peptide nucleic acids and duplex RNAs. <i>Nature Protocols</i> , <b>2006</b> , 1, 436-43	18.8	37
70	Targeting peptide nucleic acid-protein conjugates to structural features within duplex DNA. <i>Bioorganic and Medicinal Chemistry</i> , <b>1995</b> , 3, 437-45	3.4	37
69	ss-siRNAs allele selectively inhibit ataxin-3 expression: multiple mechanisms for an alternative gene silencing strategy. <i>Nucleic Acids Research</i> , <b>2013</b> , 41, 9570-83	20.1	36
68	Antisense and antigene inhibition of gene expression by cell-permeable oligonucleotide-oligospermine conjugates. <i>Journal of the American Chemical Society</i> , <b>2011</b> , 133, 8404-7	16.4	33
67	Argonaute 2-dependent Regulation of Gene Expression by Single-stranded miRNA Mimics. <i>Molecular Therapy</i> , <b>2016</b> , 24, 946-55	11.7	32
66	Inhibiting gene expression with locked nucleic acids (LNAs) that target chromosomal DNA. <i>Biochemistry</i> , <b>2007</b> , 46, 7572-80	3.2	31
65	Oligonucleotides targeting TCF4 triplet repeat expansion inhibit RNA foci and mis-splicing in FuchsU dystrophy. <i>Human Molecular Genetics</i> , <b>2018</b> , 27, 1015-1026	5.6	30
64	Stable association of RNAi machinery is conserved between the cytoplasm and nucleus of human cells. <i>Rna</i> , <b>2016</b> , 22, 1085-98	5.8	30
63	RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression. <i>Nucleic Acids Research</i> , <b>2013</b> , 41, 8788-801	20.1	30

62	Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway. <i>Nucleic Acids Research</i> , <b>2012</b> , 40, 11270-80	20.1	30
61	Allele-selective inhibition of trinucleotide repeat genes. <i>Drug Discovery Today</i> , <b>2012</b> , 17, 443-50	8.8	27
60	Regulating mammalian transcription with RNA. <i>Trends in Biochemical Sciences</i> , <b>2005</b> , 30, 655-8	10.3	27
59	Rules for Strand Invasion by Chemically Modified Oligonucleotides. <i>Journal of the American Chemical Society</i> , <b>1999</b> , 121, 2012-2020	16.4	27
58	Activation of Frataxin Protein Expression by Antisense Oligonucleotides Targeting the Mutant Expanded Repeat. <i>Nucleic Acid Therapeutics</i> , <b>2018</b> , 28, 23-33	4.8	26
57	Allele-selective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs. <i>Biochemistry</i> , <b>2014</b> , 53, 4510-8	3.2	26
56	Transcriptional regulation by miRNA mimics that target sequences downstream of gene termini. <i>Molecular BioSystems</i> , <b>2011</b> , 7, 2383-8		25
55	Recognition of chromosomal DNA inside cells by locked nucleic acids. <i>Biochemistry</i> , <b>2008</b> , 47, 13147-9	3.2	25
54	Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs. <i>Nucleic Acid Therapeutics</i> , <b>2019</b> , 29, 116-122	4.8	24
53	Pathogenic C9ORF72 Antisense Repeat RNA Forms a Double Helix with Tandem C:C Mismatches. <i>Biochemistry</i> , <b>2016</b> , 55, 1283-6	3.2	24
52	Human GW182 Paralogs Are the Central Organizers for RNA-Mediated Control of Transcription. <i>Cell Reports</i> , <b>2017</b> , 20, 1543-1552	10.6	23
51	Efficient and isoform-selective inhibition of cellular gene expression by peptide nucleic acids. <i>Biochemistry</i> , <b>2004</b> , 43, 1921-7	3.2	23
50	c9orf72 Disease-Related Foci Are Each Composed of One Mutant Expanded Repeat RNA. <i>Cell Chemical Biology</i> , <b>2017</b> , 24, 141-148	8.2	22
49	Transcriptional silencing by single-stranded RNAs targeting a noncoding RNA that overlaps a gene promoter. <i>ACS Chemical Biology</i> , <b>2013</b> , 8, 122-6	4.9	22
48	HP1BP3, a Chromatin Retention Factor for Co-transcriptional MicroRNA Processing. <i>Molecular Cell</i> , <b>2016</b> , 63, 420-32	17.6	21
47	Reduced Expression of Argonaute 1, Argonaute 2, and TRBP Changes Levels and Intracellular Distribution of RNAi Factors. <i>Scientific Reports</i> , <b>2015</b> , 5, 12855	4.9	19
46	Telomerase inhibition, telomere shortening, and decreased cell proliferation by cell permeable 2'UO-methoxyethyl oligonucleotides. <i>Journal of Medicinal Chemistry</i> , <b>2002</b> , 45, 5423-5	8.3	19
45	Engineering Duplex RNAs for Challenging Targets: Recognition of GGGGCC/CCCCGG Repeats at the ALS/FTD C9orf72 Locus. <i>Chemistry and Biology</i> , <b>2015</b> , 22, 1505-1511		17

44	Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis-o-(aminoethoxy)phenyl]pyrrolocytosine. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2009</b> , 19, 6181-4	2.9	17
43	Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs. <i>Nucleic Acid Therapeutics</i> , <b>2017</b> , 27, 87-94	4.8	16
42	Allele-selective inhibition of expression of huntingtin and ataxin-3 by RNA duplexes containing unlocked nucleic acid substitutions. <i>Biochemistry</i> , <b>2013</b> , 52, 9329-38	3.2	16
41	Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs. <i>Nucleic Acid Therapeutics</i> , <b>2014</b> , 24, 199-209	4.8	15
40	The puzzle of RNAs that target gene promoters. <i>ChemBioChem</i> , <b>2009</b> , 10, 1135-9	3.8	15
39	Modulation of Splicing by Single-Stranded Silencing RNAs. <i>Nucleic Acid Therapeutics</i> , <b>2015</b> , 25, 113-20	4.8	14
38	Activating frataxin expression by single-stranded siRNAs targeting the GAA repeat expansion. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2018</b> , 28, 2850-2855	2.9	14
37	Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2006</b> , 24, 141-51	2.8	14
36	Intramolecular circularization increases efficiency of RNA sequencing and enables CLIP-Seq of nuclear RNA from human cells. <i>Nucleic Acids Research</i> , <b>2015</b> , 43, e75	20.1	11
35	Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2011</b> , 21, 5202-5	2.9	10
34	The Requirement for GW182 Scaffolding Protein Depends on Whether Argonaute Is Mediating Translation, Transcription, or Splicing. <i>Biochemistry</i> , <b>2018</b> , 57, 5247-5256	3.2	9
33	Imaging gene expression using oligonucleotides and peptide nucleic acids. <i>Journal of Cellular Biochemistry</i> , <b>2003</b> , 90, 437-42	4.7	9
32	Quantitative Studies of Muscleblind Proteins and Their Interaction With TCF4 RNA Foci Support Involvement in the Mechanism of FuchsUDystrophy <b>2019</b> , 60, 3980-3991		8
31	Argonaute binding within 3' untranslated regions poorly predicts gene repression. <i>Nucleic Acids Research</i> , <b>2020</b> , 48, 7439-7453	20.1	8
30	Duplex RNAs and ss-siRNAs Block RNA Foci Associated with FuchsUEndothelial Corneal Dystrophy. <i>Nucleic Acid Therapeutics</i> , <b>2019</b> , 29, 73-81	4.8	7
29	Analyzing pre-symptomatic tissue to gain insights into the molecular and mechanistic origins of late-onset degenerative trinucleotide repeat disease. <i>Nucleic Acids Research</i> , <b>2020</b> , 48, 6740-6758	20.1	7
28	Efficient electroporation of neuronal cells using synthetic oligonucleotides: identifying duplex RNA and antisense oligonucleotide activators of human frataxin expression. <i>Rna</i> , <b>2019</b> , 25, 1118-1129	5.8	7
27	Expression of TNRC6 (GW182) Proteins Is Not Necessary for Gene Silencing by Fully Complementary RNA Duplexes. <i>Nucleic Acid Therapeutics</i> , <b>2019</b> , 29, 323-334	4.8	7

26	Stepping toward therapeutic CRISPR. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 15536-7	11.5	7
25	Progress towards drug discovery for Friedreich's Ataxia: Identifying synthetic oligonucleotides that more potently activate expression of human frataxin protein. <i>Bioorganic and Medicinal Chemistry</i> , <b>2020</b> , 28, 115472	3.4	7
24	Reexamining assumptions about miRNA-guided gene silencing.. <i>Nucleic Acids Research</i> , <b>2021</b> ,	20.1	6
23	Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer. <i>Prostate</i> , <b>2010</b> , 70, 616-29	4.2	5
22	Peptide nucleic acids: Cellular delivery and recognition of DNA and RNA targets. <i>International Journal of Peptide Research and Therapeutics</i> , <b>2003</b> , 10, 347-352	2.1	5
21	Challenges and Opportunities for Nucleic Acid Therapeutics.. <i>Nucleic Acid Therapeutics</i> , <b>2021</b> ,	4.8	5
20	Effect of 2'UO-methyl/thiophosphonoacetate-modified antisense oligonucleotides on huntingtin expression in patient-derived cells. <i>Artificial DNA, PNA &amp; XNA</i> , <b>2014</b> , 5, e1146391		4
19	Trinucleotide Repeat-Targeting dCas9 as a Therapeutic Strategy for Fuchs' Endothelial Corneal Dystrophy. <i>Translational Vision Science and Technology</i> , <b>2020</b> , 9, 47	3.3	4
18	Argonaute binding within human nuclear RNA and its impact on alternative splicing. <i>Rna</i> , <b>2021</b> , 27, 991-1003	10.8	4
17	Synthetic Nucleic Acids and Treatment of Neurological Diseases. <i>JAMA Neurology</i> , <b>2016</b> , 73, 1238-1242	17.2	4
16	Synthesis of oligonucleotide-peptide and oligonucleotide-protein conjugates. <i>Methods in Molecular Biology</i> , <b>2004</b> , 283, 197-206	1.4	3
15	RNA-Mediated Gene Activation: Identifying a Candidate RNA for Preclinical Development. <i>Advances in Experimental Medicine and Biology</i> , <b>2017</b> , 983, 161-171	3.6	3
14	Recognition of chromosomal DNA in human cells by peptide nucleic acids and small duplex RNAs. <i>Annals of the New York Academy of Sciences</i> , <b>2005</b> , 1058, 16-25	6.5	2
13	Identification and validation of miRNA target sites within nontraditional miRNA targets. <i>Methods in Molecular Biology</i> , <b>2015</b> , 1206, 53-67	1.4	2
12	Impact of scaffolding protein TNRC6 paralogs on gene expression and splicing. <i>Rna</i> , <b>2021</b> , 27, 1004-1016	5.8	2
11	Doubts About Therapy for Neurological Diseases With Antisense Oligonucleotides-Reply. <i>JAMA Neurology</i> , <b>2016</b> , 73, 1502-1503	17.2	1
10	Calcium liberates PNAs from endosomes. <i>Chemistry and Biology</i> , <b>2005</b> , 12, 864-5		1
9	Strand invasion by DNA-peptide conjugates and peptide nucleic acids. <i>Nucleic Acids Symposium Series</i> , <b>1999</b> , 141-2		1



8	Limits of using oligonucleotides for allele-selective inhibition at trinucleotide repeat sequences - targeting the CAG repeat within ataxin-1. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , <b>2020</b> , 39, 185-194	1.4	1
7	Difficulties translating antisense-mediated activation of Frataxin expression from cell culture to mice.. <i>RNA Biology</i> , <b>2022</b> , 19, 364-372	4.8	1
6	Targeting 3Uand 5Utranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression. <i>Nucleic Acids Research</i> , <b>2021</b> , 49, 11560-11574	20.1	0
5	Peptide nucleic acids: Cellular delivery and recognition of DNA and RNA targets. <i>International Journal of Peptide Research and Therapeutics</i> , <b>2003</b> , 10, 347-352		
4	Validating Bioluminescence Imaging as a High-Throughput, Quantitative Modality for Assessing Tumor Burden. <i>Molecular Imaging</i> , <b>2004</b> , 3, 153535002004031	3.7	
3	Peptide nucleic acids: Cellular delivery and recognition of DNA and RNA targets. <i>International Journal of Peptide Research and Therapeutics</i> , <b>2005</b> , 10, 347-352	2.1	
2	Peptide Nucleic Acids <b>2006</b> , 236-242		
1	Argonaute and TNRC6, partners in RNAi <b>2022</b> , 17-36		